Neu-Isenburg
Neu-Isenburg
Neu-Isenburg, Germany11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-08 | NCT06052267 | |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06664619 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Not applicable | 2026-08-31 | NCT07108166 | |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05878769 | |
| A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-08-12 | NCT06748053 | |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Chronic Cough, Cough, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Signs and Symptoms, Signs and Symptoms, Respiratory, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-07-14 | NCT05600777 | |
| Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-06-25 | NCT07301736 | |
| Real-World Evidence: Effectiveness and Safety of Chronic Hand Eczema Treatment With Delgocitinib Cream | Chronic Hand Eczema (CHE) | Enrolling by invitation | Not stated | 2026-05-22 | NCT07603193 | |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-05-20 | NCT05595642 | |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 3 | 2026-05-13 | NCT06750289 |